Clinical Trials

MainTitle

Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine

This study has been completed
Sponsor
International AIDS Vaccine Initiative


Information provided by (Responsible Party)
International AIDS Vaccine Initiative
ClinicalTrials.gov Identifier
NCT00902824

First received: May 13, 2009
Last updated: February 8, 2013
Last Verified: February 2013
History of Changes
Purpose

Purpose

This trial will study a prime-boost vaccine approach designed mainly to induce cell-mediated immune (CTL) responses.

Condition Intervention Phase
HIV Infections

Biological : ADVAX
Biological : TBC-M4
Other : Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Phase I Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of TBC-M4 (MVA Based HIV Vaccine) Alone or in a Prime-Boost Regimen With ADVAX, DNA HIV Vaccine

Further study details as provided by International AIDS Vaccine Initiative:

Primary Outcome Measures

  • Safety of TBC-M4 alone or in a prime-boost regimen with ADVAX [ Time Frame: 12 months ]
    Safety and tolerability of TBC-M4 alone (given im) or in a prime-boost regimen with ADVAX (administered by Biojector)
Secondary Outcome Measures:
  • Immunogenicity of TBM-M4 alone or in a prime-boost regimen with ADVAX [ Time Frame: 12 months ]

Enrollment: 32
Study Start Date: November 2008
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Active Comparator: Group A
ADVAX at 0,1 and 2 months followed by TBC-M4 at 6 months Number of volunteers: 12
Biological: ADVAX

Receive 4mg ADVAX at Months 0, 1, and 2 (Biojector), and receive boost of 5x10^7 pfu TBC-M4 (IM)

Active Comparator: Group B
TBC-M4 at 0,1,6 months Number of volunteers: 12
Biological: TBC-M4

Receive 5x10^7 pfu TBC-M4 (IM) at Months 0, 1, and 6.

Placebo Comparator: Placebo
Both Groups A and B will have 4 volunteers each (8 total) that will receive a placebo.
Other: Placebo
  • Group A (n=4) will receive the ADVAX placebo (formulation buffer) via Biojector.
  • Group B (n=4) will receive the TBC-M4 placebo (formulation buffer) via IM.

Detailed Description:

Two vaccine candidates will be used in two different prime-boost regimens: ADVAX (DNA) + TBC-M4 (MVA) and TBC-M4 (MVA) alone. Both these vaccines have already been tested in humans and both were found to be well tolerated and immunogenic. Approximately 32 volunteers (24 vaccine /8 placebo recipients) will be included in the study.

Eligibility

Eligibility

Ages Eligible for Study: 18 Years to 50 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: Yes  

Criteria

Inclusion criteria:

  • At least 18 years of age on the day of screening and no greater than 50 years (i.e., had not reached his/her 51st birthday) on the day of first vaccination;
  • Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study;
  • In the opinion of the Principal Investigator or designee, has understood the information provided. Written informed consent needs to be given before any study-related procedures are performed;
  • Willing to undergo HIV Testing, HIV counselling and receive HIV test results;
  • If sexually active female, using an effective method of contraception (hormonal contraceptive; diaphragm; intrauterine device (IUD); condoms; anatomical sterility in self or partner) from screening until at least 4 months after last vaccination. All female volunteers must be willing to undergo urine pregnancy tests at time points as indicated in the Schedule of Procedures (Appendix A);
  • If sexually active male, willing to use an effective method of contraception (such as condoms, anatomical sterility) from the day of enrolment until at least 4 months after the last vaccination;
  • Willing to forgo donations of blood, sperm, eggs, bone marrow or organs during the study.


Exclusion Criteria:
  • Confirmed HIV-1 or HIV-2 infection;
  • High-risk behaviour for HIV infection which is defined as (Within 6 months before vaccination, the volunteer has):
    • Had unprotected vaginal or anal sex with a known HIV infected person or a casual partner (i.e., no continuing established relationship)
    • Engaged in sex work for money or drugs
    • Substance abuse/use injection drugs
    • Acquired a sexually transmitted disease (STD) (e.g., gonorrhoea, chlamydia, syphilis, Trichomonas vaginalis, and symptomatic herpes genitalis)
    • Having a high-risk partner either currently or within the previous 6 months
  • Any clinically significant abnormality on history or examination including history of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive, antiviral, anticancer, or other medications considered significant by the investigator within the previous 6 months; (Note: use of inhaled steroids for asthma and use of topical steroids for localized skin conditions will not exclude a volunteer from participation.)
  • Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the investigator would make the volunteer unsuitable for the study;
  • Any of the following abnormal laboratory parameters listed below:
    • Haemoglobin <10.0 g/dL
    • Absolute Neutrophil Count (ANL): <1,000/mm3
    • Absolute Lymphocyte Count (ALC): <600/mm3
    • Platelets: <100,000/mm3
    • Creatinine: >1.3 x ULN
    • AST: >2.5 x ULN
    • ALT: >2.5 x ULN
    • Cardiac Troponin I: > ULN
    • Urinalysis: Abnormal dipstick confirmed by microscopy:
      • blood = 3+ or more (not due to menses)
      • protein = 3+ or more
      • leucocytes = 3+ or more
  • Confirmed diagnosis of hepatitis B (HBsAg), hepatitis C (HCV antibodies), or active syphilis;
  • If female, pregnant or planning a pregnancy within 4 months after last vaccination; or lactating;
  • Receipt of live attenuated vaccine within the previous 60 days (live attenuated flu vaccine within 14 days) or planned receipt within 60 days after vaccination with Investigational Product or receipt of other vaccine within the previous 14 days or planned receipt within 14 days after vaccination with Investigational Product;
  • Receipt of blood transfusion or blood products within the previous 6 months.
  • Participation in another clinical study of an investigational product currently, within the previous 3 months or expected participation during this study;
  • Receipt of another investigational HIV vaccine in the last 6 years (note: receipt of an HIV vaccine placebo will not exclude a subject from participation if documentation is available to the study site and the IAVI Medical Monitor gives approval);
  • History of severe local or systemic reactogenicity to vaccines or history of severe allergic reactions;
  • Major psychiatric illness including any history of schizophrenia or severe psychosis, bipolar disorder requiring therapy, suicidal attempt or ideation in the previous 3 years;
  • Smallpox vaccination within the previous 3 years;
  • ECG with clinically significant findings or features that would interfere with the assessment of myopericarditis, including but not limited to:
    • Conduction disturbance (atrio-ventricular or intra-ventricular conduction, left or right bundle branch block, AV block of any degree, or QTc prolongation)
    • Repolarization (ST segment or T wave) abnormality
    • Significant atrial or ventricular arrhythmia
    • Frequent atrial or ventricular arrhythmia
    • Frequent atrial or ventricular ectopy (e.g., frequent premature atrial contractions, two premature ventricular contractions in a row)
    • ST elevation consistent with ischemia
    • Evidence of past or evolving myocardial infarction (heart attack).
  • History of, or known active cardiac disease, including but not limited to:
    • Previous myocardial infarction
    • Angina pectoris
    • Congestive heart failure
    • Valvular heart disease, including mitral valve prolapse
    • Cardiomyopathy
    • Pericarditis
    • Stroke or transient ischemic attack
    • Chest pain or shortness of breath with activity (such as walking up stairs)
    • Other heart conditions under the care of a doctor.
  • Have 3 or more of the following risk factors:
    • High blood pressure diagnosed by a doctor
    • High blood cholesterol diagnosed by a doctor
    • Diabetes
    • High blood sugar diagnosed by a doctor
    • First degree relative (e.g., mother, father, brother, sister) who had a heart condition before the age of 50
    • Smoke cigarettes now.

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00902824

Locations

United Kingdom
St Stephen's Centre Chelsea and Westminster Hospital
London, United Kingdom, SW10 9NH

Sponsors and Collaborators

International AIDS Vaccine Initiative

Investigators

Principal Investigator: Brian Gazzard, MD St. Stephen's Centre
More Information

More Information

Additional Information:

International AIDS Vaccine Initiative

Responsible Party: International AIDS Vaccine Initiative  
ClinicalTrials.gov Identifier: NCT00902824   History of Changes  
Other Study ID Numbers: IAVI P002  
Study First Received: May 13, 2009  
Last Updated: February 8, 2013  

Keywords provided by International AIDS Vaccine Initiative:

HIV

Additional relevant MeSH terms:
HIV Infections
Vaccines

ClinicalTrials.gov processed this data on December 08, 2017
This information is provided by ClinicalTrials.gov.